RT Journal Article
T1 Viral protein-based nanoparticles (part 2): Pharmaceutical applications
A1 Mellid Carballal, Rocío
A1 Gutiérrez Gutiérrez, Sara
A1 Rivas, Carmen
A1 García Fuentes, Marcos
K1 Virus-like particles
K1 Virosomes
K1 Vaccines
K1 Immunostimulation
K1 Drug delivery
K1 Diagnostics
AB Viral protein nanoparticles (ViP NPs) such as virus-like particles and virosomes are structures halfway between viruses and synthetic nanoparticles. The biological nature of ViP NPs endows them with the biocompatibility, biodegradability, and functional properties that many synthetic nanoparticles lack. At the same time, the absence of a viral genome avoids the safety concerns of viruses. Such characteristics of ViP NPs offer a myriad of opportunities for theirapplication at several points across disease development: from prophylaxis to diagnosis and treatment. ViP NPs present remarkable immunostimulant properties, and thus the vaccination field has benefited the most from these platforms capable of overcoming the limitations of both traditional and subunit vaccines. This was reflected in the marketing authorization of several VLP- and virosome-based vaccines. Besides, ViP NPs inherit the ability of viruses to deliver their cargo to target cells. Because of that, ViP NPs are promising candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze the pharmaceutical applications of ViP NPs, describing the products that are commercially available or under clinical evaluation, but also the advances that scientists are making toward the implementation of ViP NPs in other areas of major pharmaceutical interest
PB Elsevier
SN 0928-0987
YR 2023
FD 2023-08-09
LK http://hdl.handle.net/10347/31218
UL http://hdl.handle.net/10347/31218
LA eng
NO European Journal of Pharmaceutical Sciences 189 (2023) 106558
NO This publication is part of the following grants: PID2021–124986OB-I00 (Project “IMMMA”) funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”; AC21_2/00046 (Project “RAIN”) funded by Health Institute Carlos III/MCIN/AEI/ 10.13039/501100011033 and by “European Union NextGenerationEU/EURONANOMED 3; PID2021–126510NB-I00 funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”; and ED431G 2019/02 grant funded by Xunta de Galicia. RMC is a recipient of a predoctoral grant from the Ministerio de Educación y Formación Profesional (FPU20/01525)
DS Minerva
RD 23 abr 2026